Preclinical-stage oncology biotechnology company developing antibody-based cancer therapies against dPSA, a tumor-associated polysaccharide involved in immune shielding
Preclinical-stage oncology biotechnology company developing antibody-based cancer therapies against dPSA, a tumor-associated polysaccharide involved in immune shielding. Its lead program, SAC-253, is a first-in-class antibody-drug conjugate, with additional antibody formats and diagnostic screening applications under development.